[go: up one dir, main page]

MX2020001434A - Analogos de insulina acilados novedosos y usos de estos. - Google Patents

Analogos de insulina acilados novedosos y usos de estos.

Info

Publication number
MX2020001434A
MX2020001434A MX2020001434A MX2020001434A MX2020001434A MX 2020001434 A MX2020001434 A MX 2020001434A MX 2020001434 A MX2020001434 A MX 2020001434A MX 2020001434 A MX2020001434 A MX 2020001434A MX 2020001434 A MX2020001434 A MX 2020001434A
Authority
MX
Mexico
Prior art keywords
insulin analogues
acylated insulin
novel acylated
novel
analogues
Prior art date
Application number
MX2020001434A
Other languages
English (en)
Inventor
Schäffer Lauge
Pettersson Ingrid
Skytte Olsen Grith
Falck Hansen Bo
Slaaby Rita
Brandt Jakob
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2020001434A publication Critical patent/MX2020001434A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)

Abstract

La presente invención se refiere a análogos de insulina novedosos y derivados de estos, tales como análogos de insulina acilados, y su uso farmacéutico, en particular en el tratamiento o prevención de afecciones médicas relacionadas con la diabetes, la obesidad y enfermedades cardiovasculares.
MX2020001434A 2017-08-17 2018-08-16 Analogos de insulina acilados novedosos y usos de estos. MX2020001434A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17186612 2017-08-17
EP17204872 2017-12-01
PCT/EP2018/072191 WO2019034726A1 (en) 2017-08-17 2018-08-16 NOVEL ACYLATED INSULIN ANALOGUES AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2020001434A true MX2020001434A (es) 2020-03-20

Family

ID=63165388

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001434A MX2020001434A (es) 2017-08-17 2018-08-16 Analogos de insulina acilados novedosos y usos de estos.

Country Status (19)

Country Link
US (2) US10919949B2 (es)
EP (1) EP3668892A1 (es)
JP (2) JP2020531451A (es)
KR (1) KR20200038502A (es)
CN (1) CN111032685A (es)
AU (1) AU2018317810A1 (es)
BR (1) BR112020002364A2 (es)
CA (1) CA3071686A1 (es)
CL (1) CL2020000310A1 (es)
CO (1) CO2020002500A2 (es)
IL (1) IL272394A (es)
MA (1) MA49896A (es)
MX (1) MX2020001434A (es)
PE (1) PE20211264A1 (es)
PH (1) PH12020550050A1 (es)
RU (1) RU2020108281A (es)
SG (1) SG11202001077UA (es)
TW (1) TW201917134A (es)
WO (1) WO2019034726A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1969004T3 (pl) 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
KR102873595B1 (ko) 2021-09-15 2025-10-22 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 장애의 치료를 위한 조성물 및 방법
WO2024185897A1 (ja) * 2023-03-09 2024-09-12 学校法人神戸学院 インスリンフラグメントタグ、及び医薬組成物

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE50892B1 (en) 1980-02-11 1986-08-06 Novo Industri As Process for preparing insulin esters
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5616729A (en) 1986-07-17 1997-04-01 Board Of Governors Of Wayne State University Enhanced chemiluminescence from 1,2-dioxetanes through energy transfer to tethered fluorescers
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK10191D0 (da) 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
DK33591D0 (es) 1991-02-27 1991-02-27 Novo Nordisk As
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
ZA954983B (en) 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
EP0946735B1 (en) 1996-12-20 2006-02-08 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
PT1146896E (pt) 1999-01-26 2002-10-31 Lilly Co Eli Formulacoes monodispersas de analogo acilado e hexamerico insulina
AU5144400A (en) 1999-05-19 2000-12-05 Xencor, Inc. Novel proteins with insulin-like activity useful in the treatment of diabetes
ES2307544T3 (es) 1999-12-29 2008-12-01 Novo Nordisk A/S Metodo de produccion de precursores de insulina y analogos de precursores de insulina.
ATE517119T1 (de) 2003-12-03 2011-08-15 Novo Nordisk As Einzelketteninsulin
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
ES2428510T3 (es) 2005-02-02 2013-11-08 Novo Nordisk A/S Derivados de insulina
WO2007096431A1 (en) * 2006-02-27 2007-08-30 Novo Nordisk A/S Insulin derivatives
JP5864834B2 (ja) 2006-09-22 2016-02-17 ノボ・ノルデイスク・エー／エス プロテアーゼ耐性のインスリンアナログ
EP2178912B1 (en) 2007-08-15 2015-07-08 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
JP5749155B2 (ja) * 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
WO2010080609A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
JP2012512900A (ja) 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション インスリン受容体に対して高い活性を示すｙｌ系インスリン様増殖因子
EP2376520B1 (en) 2008-12-19 2014-02-12 Indiana University Research&Technology Corporation Insulin analogs
US20120241356A1 (en) 2009-07-06 2012-09-27 Sanofi-Aventis Deutschland Gmbh Heat- and vibration-stable insulin preparations
WO2011159895A2 (en) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
WO2011159882A2 (en) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Novel stabilized insulin agonists
EP2585484A1 (en) 2010-06-23 2013-05-01 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
WO2011163460A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Yl-based insulin-like growth factors exhibiting high activity at the insulin receptor
JP5912112B2 (ja) 2010-06-24 2016-04-27 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ アミド系インスリンプロドラッグ
US9074015B2 (en) 2010-07-28 2015-07-07 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
JP2013540771A (ja) 2010-10-15 2013-11-07 ノヴォ ノルディスク アー／エス 新規ｎ末端修飾インスリン誘導体
AR087433A1 (es) 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
EP2793932B1 (en) 2011-12-20 2018-10-03 Indiana University Research and Technology Corporation Ctp-based insulin analogs for treatment of diabetes
EP2794648A1 (en) 2011-12-21 2014-10-29 Novo Nordisk A/S N-terminally modified insulin derivatives
CN104981251B (zh) 2012-09-26 2018-03-20 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
EP2925345B1 (en) 2012-12-03 2018-09-05 Merck Sharp & Dohme Corp. Method for making o-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
WO2014099577A1 (en) 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. Process for purifying insulin and analogues thereof
KR20150131213A (ko) 2013-03-14 2015-11-24 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 인슐린-인크레틴 접합체들
WO2015010927A1 (en) 2013-07-24 2015-01-29 Novo Nordisk A/S Pharmaceutical composition for oral insulin administration comprising a tablet core and an anionic copolymer coating
BR112016007176A2 (pt) 2013-10-04 2018-01-23 Merck Sharp & Dohme conjugado, composição, usos de um conjugado e de uma composição, e, método para tratar um indivíduo que tem diabete
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
ES2822994T3 (es) 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Conjugados de incretina-insulina
EP3197912B1 (en) 2014-09-24 2023-01-04 Indiana University Research & Technology Corporation Lipidated amide-based insulin prodrugs
CA3014641C (en) 2014-11-21 2020-08-18 Songnian Lin Insulin receptor partial agonists
US20180000742A1 (en) 2015-01-29 2018-01-04 Novo Nordisk A/S Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and a Polyvinyl Alcohol Coating
WO2016144658A1 (en) 2015-03-10 2016-09-15 Merck Sharp & Dohme Corp. Process for preparing recombinant insulin using microfiltration
US20180110863A1 (en) 2015-04-08 2018-04-26 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
WO2016172269A2 (en) 2015-04-20 2016-10-27 University Of Utah Research Foundation Insulin analogs having shortened b chain peptides and associated methods
JP2018531901A (ja) * 2015-08-25 2018-11-01 ノヴォ ノルディスク アー／エス 新規インスリン誘導体及びその医学的使用
CN108368163A (zh) * 2015-08-25 2018-08-03 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
JP2018531900A (ja) * 2015-08-25 2018-11-01 ノヴォ ノルディスク アー／エス 新規インスリン誘導体及びその医学的使用
US10745457B2 (en) 2015-09-02 2020-08-18 Merck Sharp & Dohme Corp. Process for obtaining insulin with correctly formed disulfide bonds

Also Published As

Publication number Publication date
CN111032685A (zh) 2020-04-17
JP2020531451A (ja) 2020-11-05
CL2020000310A1 (es) 2020-07-10
MA49896A (fr) 2020-06-24
PE20211264A1 (es) 2021-07-15
US20210094999A1 (en) 2021-04-01
EP3668892A1 (en) 2020-06-24
TW201917134A (zh) 2019-05-01
CA3071686A1 (en) 2019-02-21
RU2020108281A3 (es) 2022-03-09
SG11202001077UA (en) 2020-03-30
WO2019034726A1 (en) 2019-02-21
JP2022105082A (ja) 2022-07-12
KR20200038502A (ko) 2020-04-13
IL272394A (en) 2020-03-31
US10919949B2 (en) 2021-02-16
RU2020108281A (ru) 2021-08-26
PH12020550050A1 (en) 2020-10-19
AU2018317810A1 (en) 2020-03-19
BR112020002364A2 (pt) 2020-09-01
CO2020002500A2 (es) 2020-06-09
US20190194285A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
WO2015128403A3 (en) An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue
SA519401239B1 (ar) نظائر أميلين
SA519401933B1 (ar) تركيبات صيدلية تحتوي على الأنسولين
MA49339A (fr) Conjugués insuline-fc à extension oligomère
MX2017011182A (es) Analogos de amilina.
PH12016501724A1 (en) Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
MX2016013029A (es) Compuestos de indanona sustituidos como modulares de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados.
ZA202000375B (en) Compounds for the prevention and treatment of medical disorders and uses thereof
JOP20210201A1 (ar) مركب لخفض جلوكوز الدم
PH12019502655A1 (en) Acylated insulin compound
MX2018001733A (es) Compuestos heterocíclicos de fumagillol y métodos de elaboración y uso de los mismos.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2019003725A (es) Glicinato de metformina, composiciones farmaceuticas que comprenden la misma, y metodos de uso de la misma.
PH12022551094A1 (en) Novel insulin analogues and uses thereof
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2018000418A (es) Derivados de amida que tienen actividad multimodal contra el dolor.
EA201400536A1 (ru) Способы получения двойных солей лоркасерина (варианты), продукты способов, двойные соли, фармацевтические композиции для лечения и/или профилактики нарушений, связанных с ожирением, их применение и способ лечения и/или профилактики нарушений, связанных с ожирением
HK1223287A1 (zh) 治疗性同源二聚体及其用途
HK1242712A1 (en) Amylin analogues
LV15072A (lv) Farmaceitiska kompozīcija izmantošanai patoloģiska stāvokļa, kam raksturīga paaugstināta iNOS gēna ekspresija, profilaksei un ārstēšanai
IN2014MU00186A (es)